[Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
The treatment of 34 patients with secondary aldosteronism with a new oral and parenteral preparation (Osyrol) is reported. On the strength of the clinical results with remissions of signs of heart failure and increase in the volume of urine, reduction of body weight and raising of serum potassium, the efficacy of the preparation with good general and local tolerance is described.
D000284:Administration, Oral; D000368:Aged; D001794:Blood Pressure; D001835:Body Weight; D002191:Canrenoic Acid / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D007267:Injections; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D009318:Natriuresis; D011188:Potassium / Q000097:blood / Q000652:urine; D011245:Pregnadienes / Q000627:therapeutic use*; D012964:Sodium / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use*
D011245:Pregnadienes; D013148:Spironolactone; D002191:Canrenoic Acid; D012964:Sodium; D011188:Potassium
Klinische Erfahrungen bei der Anwendung von Osyrol 100 und Osyrol pro injectione